India's weight-loss market grows up

Availability of cheaper generic anti-obesity drugs has not resulted in a rush to your local drugstore. The relatively early flattening of India's anti-obesity drug market marks a certain maturity, allowing market forces, sensible regulation and improved awareness to shape behaviour, rather than relying on a heavy-handed ban.

The early surge of adopters consisted largely of more affluent users, for whom weight loss, rather than price, was the primary consideration. The next group of eligible consumers is more price-conscious, and although generic brands are cheaper, their cost remains substantial. What makes sales trajectory of these rapid weight-loss drugs noteworthy, however, is the way caution and open access have been balanced.

Semaglutide wasn't banned. Instead, 13 pharmaceutical companies launched 26 generic brands, while GoI relied on raising awareness and putting guard rails in place. Drug regulators issued advisories prohibiting D2C advertising and promotion of prescription weight-loss drugs, while also tracking unauthorised sales through gym trainers, dieticians and online pharmacies to prevent misuse.


Perhaps the most important factor shifting consumers away from viewing GLP-1 drugs as an easy weight-loss option has been efforts to address the info asymmetry that plagues pharma markets. Medical professionals and trustworthy institutions focused on raising awareness about the serious side effects associated with misuse, including muscle loss, malnutrition, pancreatitis and rapid weight regain once the medication is discontinued. Better understanding and wider dissemination of safety-related information, including data on adverse reactions, help create informed consumers rather than consumers seeking quick fixes.